Semaglutide, a glucagon like peptide-one (GLP-1) receptor agonist, is available as monotherapy in both subcutaneous and oral dosage variety (to start with accepted oral GLP-one receptor agonist). It has been approved like a second line therapy selection for much better glycaemic Manage in type two diabetic issues and at present https://johni655vhr7.wikipublicity.com/user